Amyotrophic lateral sclerosis and intestinal microbiota—toward establishing cause and effect
The intestinal microbiota may be involved, through metabolic gut–brain interactions, in a variety of neurological conditions. In this addendum, we summarize the findings of our recent study investigating the potentially modulatory influence of the microbiome in a transgenic ALS mouse model, and the...
Main Authors: | Marc Gotkine, Denise Kviatcovsky, Eran Elinav |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-11-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/19490976.2020.1767464 |
Similar Items
-
Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis
by: Erika L.F. Holzbaur, et al.
Published: (2006-09-01) -
Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice
by: Judyta K Juranek, et al.
Published: (2016-05-01) -
Calcium dysregulation, mitochondrial pathology and protein aggregation in a culture model of amyotrophic lateral sclerosis: Mechanistic relationship and differential sensitivity to intervention
by: Miranda L. Tradewell, et al.
Published: (2011-06-01) -
The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
by: Sarah L. Boddy, et al.
Published: (2021-01-01) -
Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials
by: Syed I. Khalid, et al.
Published: (2017-09-01)